Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. Our novel, proprietary pipeline products – including XEN496, XEN1101 and XEN007 – are aimed at treating neurological disorders, with a particular focus on epilepsy. We also have promising partnered products within our pipeline, such as NBI-921352 with Neurocrine Biosciences and FX301 with Flexion Therapeutics. For more information, please visit www.xenon-pharma.com.
Jodi Regts
